HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits

Pharmacological Research

Volumn 48, Issue 5, 2003, Pages 417-427

  Mitani, Hironobu ^a   Egashira, Kensuke ^b   Kimura, Masaaki ^a  

^a NOVARTIS PHARMA K K   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Aorta; Atherosclerosis; Drugs; Hypercholesterolemia; Pharmacology

Indexed keywords

COLONY STIMULATING FACTOR 1; DIPEPTIDYL CARBOXYPEPTIDASE; FLUINDOSTATIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EXTRACELLULAR MATRIX; LIPID STORAGE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REDUCTION; SMOOTH MUSCLE FIBER;

EID: 0041326555     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00184-1     Document Type: Article

References (36)

1. Ballantyne C.M., Herd J.A., Ferlic L.L., Dunn J.K., Farmer J.A., Jones P.H.et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 99:1999;736-743.
2. Serruys P.W., Foley D.P., Jackson G., Bonnier H., Macaya C., Vrolix M.et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. 20:1999;58-69.
3. Riegger G., Abletshauser C., Ludwig M., Schwandt P., Widimsky J., Weidinger G.et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 144:1999;263-270.
4. Mitani H., Kimura M. Fluvastatin, HMG-CoA reductase inhibitor: antiatherogenic profiles through its lipid-lowering-dependent and -independent actions. Cardiovasc. Drug Rev. 18:2000;284-303.
5. Corsini A. Fluvastatin: effects beyond cholesterol lowering. J. Cardiovasc. Pharmacol. Ther. 5:2000;161-175.
6. Sumi D., Hayashi T., Thakur N.K., Jayachandran M., Asai Y., Kano H.et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis. 155:2001;347-357.
7. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M.et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 154:2001;87-96.
8. Bandoh T., Mitani H., Niihashi M., Kusumi Y., Kimura M., Ishikawa J.et al. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J. Cardiovasc. Pharmacol. 35:2000;136-144.
9. Tomita H., Egashira K., Kubo-Inoue M., Usui M., Koyanagi M., Shimokawa H.et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler. Thromb. Vasc. Biol. 18:1998;1456-1464.
10. Koyanagi M., Egashira K., Kitamoto S., Ni W., Shimokawa H., Takeya M.et al. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation. 102:2000;2243-2248.
11. Ni W., Egashira K., Kitamoto S., Kataoka C., Koyanagi M., Inoue S.et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation. 103:2001;2096-2101.
12. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:1998;894-897.
13. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., Yoshida M., Ding H.A., Gimbrone M.A. Jr.et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 398:1999;718-723.
14. Libby P., Geng Y.J., Aikawa M., Schoenbeck U., Mach F., Clinton S.K.et al. Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 7:1996;330-335.
15. George S.J. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin. Invest. Drugs. 9:2000;993-1007.
16. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y.et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 103:2001;993-999.
17. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y.et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 103:2001;276-283.
18. Shiomi M., Ito T., Hirouchi Y., Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis. 157:2001;75-84.
19. Mitani H., Bandoh T., Ishikawa J., Kimura M., Totsuka T., Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br. J. Pharmacol. 119:1996;1269-1275.
20. Mitani H., Bandoh T., Kimura M., Totsuka T., Hayashi S. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am. J. Physiol. 271:1996;H1065-H1071.
21. Shiomi M., Shiraishi M., Yata T., Ito T. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung. 44:1994;1154-1156.
22. Shiomi M., Ito T., Tsukada T., Yata T., Ueda M. Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ. An immunohistochemical study. Arterioscler. Thromb. 14:1994;931-937.
23. Fujisawa T., Hattori T., Takahashi K., Kuboki T., Yamashita A., Takigawa M. Cyclic mechanical stress induces extracellular matrix degradation in cultured chondrocytes via gene expression of matrix metalloproteinases and interleukin-1. J. Biochem. (Tokyo). 125:1999;966-975.
24. Sugano M., Makino N., Yanaga T. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis. 127:1996;123-129.
25. Fruebis J., Gonzalez V., Silvestre M., Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17:1997;1289-1302.
26. Pervin S., Singh R., Rosenfeld M.E., Navab M., Chaudhuri G., Nathan L. Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 18:1998;1575-1582.
27. Palacios I., Lopez-Armada M.J., Hernandez P., Sanchez-Pernaute O., Gutierrez S., Miguelez R.et al. Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. Clin. Exp. Immunol. 111:1998;588-596.
28. Fleet J.C., Clinton S.K., Salomon R.N., Loppnow H., Libby P. Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. J. Nutr. 122:1992;294-305.
29. Tse F.L., Jaffe J.M., Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol. 32:1992;630-638.
30. Kantola T., Backman J.T., Niemi M., Kivisto K.T., Neuvonen P.J. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56:2000;225-229.
31. Herd J.A. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. Am. J. Med. 104:1998;42S-49S.
32. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R. et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18:1998;1671-1678.
33. Ganne F., Vasse M., Beaudeux J.L., Peynet J., Francois A., Mishal Z.et al. Cerivastatin an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb. Haemost. 84:2000;680-688.
34. Wong B., Lumma W.C., Smith A.M., Sisko J.T., Wright S.D., Cai T.Q. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol. 69:2001;959-962.
35. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;265-272.
36. Hamilton J.A., Myers D., Jessup W., Cochrane F., Byrne R., Whitty G.et al. Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF. Arterioscler. Thromb. Vasc. Biol. 19:1999;98-105.